Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia

F. Locatelli, J.A. Whitlock, C. Peters, C. Chen-Santel, V. Chia, R.M. Dennis, K.M. Heym, A.J. Katz, M.A. Kelsh, R. Sposto, H. Tu, C.A. Tuglus, A. Verma, L. Vinti, J.J. Wilkes, N. Zubarovskaja, G. Zugmaier, A. von Stackelberg, W. Sun

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)2473-2478
Number of pages6
JournalLeukemia
Volume34
Issue number9
DOIs
Publication statusPublished - 2020

Keywords

  • blinatumomab
  • antineoplastic agent
  • bispecific antibody
  • acute lymphoblastic leukemia
  • aging
  • Australia
  • blast cell
  • blood cell count
  • Canada
  • cancer chemotherapy
  • cancer combination chemotherapy
  • cancer prognosis
  • chromosome 11q
  • comparative study
  • drug efficacy
  • Europe
  • follow up
  • hematopoietic stem cell transplantation
  • human
  • intensive care
  • Letter
  • leukemia relapse
  • North America
  • overall survival
  • phase 1 clinical trial (topic)
  • phase 2 clinical trial (topic)
  • Philadelphia chromosome negative cell
  • priority journal
  • risk factor
  • salvage therapy
  • sample size
  • sex ratio
  • therapy effect
  • treatment outcome
  • United States
  • adolescent
  • child
  • female
  • genetics
  • male
  • Philadelphia 1 chromosome
  • preschool child
  • recurrent disease
  • Adolescent
  • Antibodies, Bispecific
  • Antineoplastic Agents
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Male
  • Philadelphia Chromosome
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
  • Recurrence

Cite this